Systematic review and meta-analysis of Saccharomyces boulardii in adult patients

Table 5 Randomized, controlled trials for chronic disease conditions using S. boulardii

Ref.	Treatment groups	Study population	Daily dose: cfu/d (mg/d)	Duration of treatment and follow-up	Outcome in probiotic	Outcome in controls
	Crohn’s disease
Plein et al[57]	S. boulardii (Perenterol®) vs placebo	20 enrolled with Crohn’s, 17 done, all on maintenance medications	1.5 × 1010 (750 mg)	7 wk	3.3 ± 1.2 stools/d at week 9a	4.6 ± 1.9 stools/d at week 9
Guslandi et al[47]	S. boulardii (Perenterol®) + mesalamine (2 g/d) vs mesalamine alone (3 g/d)	32 with Crohn’s in remission in Italy (23-49 yr old)	2 × 1010 (1000 mg)	6 mo	1/16 (6%) relapsea	6/16 (38%) relapse
	Irritable bowel syndrome
Maupas et al[52]	S. boulardii vs placebo	34 with IBS	9 × 109 (nr)	4 wk	Mean decrease in #stools/d: -2.2/da	Mean decrease -0.5/d
					Improved: 14/16 (87.5%)a	Improved: 13/18 (72%)
	Giardiasis
Besirbellioglu et al[38]	S. boulardii + metro (2250 mg/d) vs placebo + metro	65 adults with giardiasis	1 × 1010 (500 mg)	10 d with 4 wk f/up	100% cured, 0% giardia cystsa	100% cured 6/35 (17%) cysts present
	HIV-related diarrhea
Saint- Marc et al[189]	S. boulardii vs placebo	35 French AIDS patients with chronic diarrhea	6 × 1010 (3000 mg)	7 d	11/18 (61%) cureda	2/17 (12%)

^aP < 0.05, probiotic vs controls. IBS: Irritable bowel syndrome; HIV: Human immunodeficiency virus; AIDS: Acquired immune deficiency syndrome; f/up: Follow-up time.